Related Experiment Video

Updated: Sep 27, 2025

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.1K

Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease

Ping Wang1, Jun Ma2, Ru Zhang1

  • 1Department of Geriatrics, The General Hospital of Western Theater Command, Chengdu, Sichuan, 610083; P.R. China.

Endocrine, Metabolic & Immune Disorders Drug Targets
|April 8, 2022
PubMed

Insights

Interleukin 1β monoclonal antibody therapy shows promise for coronary artery disease by reducing inflammation. Targeting the inflammasome offers a new strategy to further combat residual inflammation in atherosclerotic disease.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Coronary artery disease (CAD) treatment has advanced with anti-inflammatory therapies like interleukin 1β (IL-1β) monoclonal antibodies, improving patient prognosis irrespective of lipid levels.
  • Despite advancements, residual inflammation persists in patients treated with IL-1β inhibitors, highlighting the need for novel therapeutic strategies.
  • The inflammasome, a key intracellular inflammatory complex, plays a critical role in the pathogenesis of atherosclerosis.

Approach:

  • This review synthesizes current research on the role and mechanisms of inflammasomes in the development and progression of atherosclerotic disease.
  • It examines the potential of targeting inflammasome pathways as a novel anti-inflammatory approach for managing residual inflammation in CAD.
  • The review identifies and discusses existing drugs with potential anti-inflammasome activity for treating atherosclerosis.

Key Points:

  • IL-1β monoclonal antibodies offer a new therapeutic avenue for CAD, demonstrating efficacy beyond lipid management.
  • Inflammasome activation is a critical driver of residual inflammation in atherosclerosis.
  • Targeting inflammasomes presents a promising strategy for developing next-generation anti-inflammatory treatments for atherosclerotic disease.

Conclusions:

  • Anti-inflammatory treatments targeting IL-1β have shown efficacy in CAD, but residual inflammation remains a challenge.
  • Modulating inflammasome pathways offers a potential mechanism to address persistent inflammation in atherosclerosis.
  • Further research into inflammasome inhibitors could lead to improved therapies for preventing and treating atherosclerotic disease.

Keywords:
1β monoclonal antibodyAtherosclerotic diseasecoronary artery diseaseinflammasomesinterleukin 18interleukin 1β

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.3K
Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages08:41

Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages

Published on: April 6, 2022

2.8K

Related Concept Videos

Inflammation01:38

Inflammation

Overview
55.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
132
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
99
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
62
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
42